abrdn Life Sciences Investors Business Summary

abrdn Life Sciences Investors (HQL) is a non-diversified, closed-end management investment company that generates revenue through management fees—fixed at approximately 1.04% of net assets—and capital appreciation from its diversified portfolio of public and private equity. The fund operates primarily within the life sciences sector, with core business segments spanning biotechnology, pharmaceuticals, medical diagnostics, and healthcare information technology. As of early 2026, HQL maintains a competitive market position by offering a high-yield distribution policy, recently increased to $0.56 per share, and frequently trading at a discount to its Net Asset Value (NAV). It competes directly with other specialized closed-end funds such as Tekla Healthcare Investors (THQ), BlackRock Science and Technology Opportunities Fund (BST), and Gabelli Equity Trust (GAB), distinguishing itself through its long-standing focus on emerging small-cap growth companies and private-stage venture investments. The fund's strategic direction is overseen by abrdn’s senior leadership, including Group CEO Jason Windsor, who assumed the role in late 2024, and Xavier Meyer, the CEO of Investments. The investment team is led by Dr. Jason Akus, M.D., MBA, who serves as the lead portfolio manager following the 2024 transition from long-time manager Dr. Daniel Omstead. The fund was originally established in 1992 as H&Q Life Sciences Investors, rooted in the pedigree of the investment bank Hambrecht & Quist, founded by Bill Hambrecht and George Quist. The Board of Trustees is chaired by Sir Douglas Flint and includes notable independent members such as Rose DiMartino and Jeffrey Bailey. Significant institutional backing is provided by Saba Capital Management, which remains a major shareholder and active participant in the fund’s governance landscape as of February 2026.